Spectrum Pharma to seek cancer drug approval in third quarter

[riky]

Spectrum Pharma to seek cancer drug approval in third quarter

Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe and effective in a key mid-stage trial. The injectable drug, Captisol-enabled melphalan, an improved form of common chemotherapy drug melphalan, is being tested in patients with multiple myeloma undergoing stem cell transplants. Roth Capital Partners analyst Joseph Pantginis said he expects CE-Melphalan to receive full approval next year. "CE-Melphalan would fit nicely with (Spectrum's) salesforce's current hematological bag," he said.

Source: You are not allowed to view links. Register or Login